| Identification | Back Directory | [Name]
Ginsenoside Rg2 | [CAS]
52286-74-5 | [Synonyms]
anaxatriol
GinsesideRg2
Panaxoside Rg2
product/154570
Ginsenosdie Rg2
PROSAPOGENIN C2
GINSENOSIDE RG2
iGInsenoside Rg2
mannopyranosyl)-
GINSENOSIDE Rg2(SH)
CHIKUSETSUSAPONIN I
Ginsenoside Rg2 ,98%
Ginsenoside 20(s)-Rg2
(20S)-Ginsenoside Rg2
CHIKUSETSUSAPONIN I, PROSAPOGENIN C2
Ginsenoside Rg2 (Chikusetsusaponin I
β-D-Glucopyranoside,(3β,6α,12β)-3,12,20-
-6-yl-2-o-(6-deoxy-alpha-l-mannopyranosyl)-
trihydroxydammar-24-en-6-yl2-O-(6-deoxy-α-L-
(6)-(alpha-l-rhamnopyranosyl(1-rham-2-glu)-beta-d-glucopyranosyl)-20s-protop
beta-d-glucopyranoside,(3-beta,6-alpha,12-beta)-3,12,20-trihydroxydammar-24-en
6α-(2-O-α-L-Rhamnopyranosyl-β-D-glucopyranosyloxy)-dammara-24-ene-3β,12β,20-triol
[3β,12β,20-Trihydroxydammar-24-en-6α-yl]2-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside
[3β,12β,20-Trihydroxy-5α-dammar-24-en-6α-yl]2-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside
(3β,6α,12β)-3,12,20-Trihydroxydammar-24-en-6-yl 2-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside
β-D-Glucopyranoside, (3β,6α,12β)-3,12,20-trihydroxydammar-24-en-6-yl 2-O-(6-deoxy-α-L-mannopyranosyl)-
b-D-Glucopyranoside, (3b,6a,12b)-3,12,20-trihydroxydammar-24-en-6-yl 2-O-(6-deoxy-a-L-mannopyranosyl)- | [Molecular Formula]
C42H72O13 | [MDL Number]
MFCD00210511 | [MOL File]
52286-74-5.mol | [Molecular Weight]
785.03 |
| Chemical Properties | Back Directory | [Melting point ]
187～189℃ | [Boiling point ]
881.0±65.0 °C(Predicted) | [density ]
1.30±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
Methanol (Slightly, Heated, Sonicated), Pyridine (Slightly, Sonicated) | [form ]
Solid | [pka]
12.85±0.70(Predicted) | [color ]
White to Off-White | [Stability:]
Hygroscopic | [InChIKey]
AGBCLJAHARWNLA-DJZXLMSJSA-N | [LogP]
6.830 (est) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
22 | [Safety Statements ]
24/25 | [WGK Germany ]
3 | [RTECS ]
LZ6430000 | [HS Code ]
29389090 | [Toxicity]
mouse,LD50,intraperitoneal,1340mg/kg (1340mg/kg),Arzneimittel-Forschung. Drug Research. Vol. 25, Pg. 343, 1975. |
| Hazard Information | Back Directory | [Description]
Ginsenosides are pharmacologically active natural compounds from ginseng and other plants of the genus Panax.1 Structurally, they are steroid glycosides derived from the triterpene squalene.1 Ginsenoside Rg2 is a protopanaxatriol that is more abundant in some Panax species (e.g., white and red P. ginseng) than others.2 This ginsenoside and its metabolites have diverse in vitro and in vivo effects, including neuroprotective, anti-inflammatory, and anti-diabetic actions.3,4,5 It also protects against DNA damage and apoptosis induced by ultraviolet light.6 Notably, this ginsenoside is increased by the metabolism of other bioactive ginsenosides during the steaming or heating of plant materials, particularly in P. quinquefolium.2,7 | [Chemical Properties]
White solid | [Uses]
20(S)-Ginsenoside Rg2 is used as an aldose reductase inhibitor and my exert anti-inflammatory and immunomodulatory activity. It exists as a bioactive metabolite of the ginsenoside component of Panax ginseng. | [Definition]
ChEBI: Ginsenoside Rg2 is a ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions, in which the hydroxy group at position 6 has been converted to the corresponding alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position. It has a role as a plant metabolite, a cardioprotective agent and an anticoagulant. It is a beta-D-glucoside, a 12beta-hydroxy steroid, a 3beta-hydroxy steroid, a ginsenoside, a tetracyclic triterpenoid, a disaccharide derivative, a 20-hydroxy steroid and a 3beta-hydroxy-4,4-dimethylsteroid. It derives from a hydride of a dammarane. | [in vivo]
G-Rg1 and Ginsenoside Rg2 (G-Rg2) reduce the escape latencies on the last two training days compared to the Alzheimer's disease (AD) model group (p<0.05). In the spatial exploration test, the total time spent in the target quadrant and the number of mice that exactly crossed the previous position of the platform are clearly shorter and lower, respectively, in the AD model group mice than in the normal control group mice (p<0.01), a trend that is reversed by treatment with G-Rg1 and Ginsenoside Rg2 (G-Rg1, p<0.01; Ginsenoside Rg2, p<0.05). Treatment with G-Rg1 and Ginsenoside Rg2 effectively improve cognitive function of the mice that have declined due to AD. G-Rg1 and Ginsenoside Rg2 reduce Aβ1-42 accumulation in APP/PS1 mice. In the G-Rg1 and Ginsenoside Rg2 treated mice, the pathological abnormalities observed in the APP/PS1 mice are gradually ameliorated. Clear nucleoli and light brown, sparsely scattered Aβ deposits are visible[2]. | [IC 50]
NF-κB; Aβ1-42 |
|
|